Dimastromatteo Julien, Houghton Jacob L, Lewis Jason S, Kelly Kimberly A
From the *Biomedical Engineering Department, University of Virginia, Robert M. Berne Cardiovascular Research Center, Charlottesville, VA; †Department of Radiology and the Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY.
Cancer J. 2015 May-Jun;21(3):188-93. doi: 10.1097/PPO.0000000000000109.
The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.
近年来，新型分子癌症成像剂的研发取得了显著进展。众多癌症成像剂在临床前阶段已展现出在辅助诊断、分期及治疗规划方面的巨大潜力，这也促使一些成像剂获批进入人体试验阶段。胰腺导管腺癌是目前最致命的常见癌症，总体5年生存率约为6%。随着检测技术的进步，开发能够实现早期诊断的分子成像工具对于改善患者预后至关重要。在本综述中，我们将重点介绍能够照亮构成肿瘤的各种细胞群体的成像剂，即上皮、内皮和基质肿瘤细胞。
